Lung Cancer

Brittney Nichols highlights the need for early detection and stresses that lung cancer is not only caused by smoking; anyone can develop the disease.

Although a cancer diagnosis can feel overwhelming and isolating, patients should know that they are never alone, Brittney Nichols emphasized.

The FDA granted fast track designation to VT3989 for unresectable malignant nonpleural or pleural mesotherlioma.

LiveLung, a nonprofit organization dedicated to supporting lung cancer patients, invites the Charlotte cancer community to its monthly educational meeting.

Dr. Nicolas Girard discussed the current treatment options for patients with EGFR-mutant lung cancer, including emerging combination regimens.

As we approach Lung Cancer Awareness Month this November, it’s important to reflect on the latest developments and insights in lung cancer research.

Dr. Fred Hirsch highlighted how knowledge of the molecular characteristics of non-small cell lung cancer enhances understanding of the disease.

In EGFR-mutated non-small cell lung cancer Tagrisso with pemetrexed and chemotherapy was associated with an improvement in survival.

Kelly Dyckman works to help women reclaim their confidence in intimacy following a cancer journey, as she explained in an interview with CURE.

The FDA has approved Zepzelca with Tecentriq or Tecentriq Hybreza for extensive-stage small cell lung cancer.

Lung cancer can be overwhelming, but learning about types, stages, treatments and support can help patients feel more prepared for their care journey.

Prior to my diagnosis with Stage 3B Lung Cancer, I had spent many years reading self-help books. I worked hard, but never felt successful, or took pride in myself.

In September 2025, the FDA approved new treatments for breast, bladder and prostate cancers, plus biosimilars and a subcutaneous immunotherapy option.

Adding Tecentriq to chemoradiation improved quality of life and supported twice-daily radiation for patients with limited-stage small cell lung cancer.

Dr. Mary B. Beasley discusses evolving role of pathologists in lung cancer care, highlighting how emerging technologies may shape the future of the field.

For patients with cancer grappling with nausea or vomiting due to their treatments, a potential side effect remedy may be found in their own hands.

Dr. Edgardo Santos explains that combining Tagrisso with chemotherapy or Leclaza plus Rybrevant may improve survival versus monotherapy alone.

Dr. Sandip Patel discusses findings from a real-world study of biomarker testing in early-stage resected non-small cell lung cancer in the U.S.

Dr. Alexander Spira explained the difference between a clinical trial and a real-world study in a CURE interview for patients with lung cancer.

Ibtrozi may become the new standard for ROS1-mutated lung cancer, with phase 2 data showing safer, longer-lasting benefits for patients.

LiveLung announced the launch of its new Chaplain Program.

It is very important to let the world know that no matter how healthy you think you are, if you have lungs, you can potentially develop lung cancer.

The FDA has granted approval to subcutaneous Keytruda for use in adults and pediatric patients with a solid tumor.

Nancee Pronsati discusses a new patient-authored guide for managing ALK-directed treatment side effects in lung cancer and improving quality of life.